Skip to content
Telehealth Graded
State guide

New York Medicaid and GLP-1s

Most states tell you what they will not cover. New York tells you what the pharmacy screen will say when it happens. Its March 2026 Medicaid Update carries a table of frequently rejected drugs with Zepbound and Wegovy in it, the edit number, the denial code, the manufacturer, and a one-line reason citing the federal statute. The same program spent the previous autumn adding a different GLP-1 restriction through its review board.

Every source on this page was read first-hand in September 2026, and each one below carries the date printed on the document itself.

2
documents cited
6
sourced facts
2
primary sources

What changed, and what the document says

  1. The reason, printed in the rejection table

    Not covered

    New York puts the statutory basis in the same row as the drug and the denial code, so the pharmacy sees the reason and the code together.

    Drugs indicated for weight loss are not covered pursuant to SSA §1927(d)(2)

    New York State Department of HealthMarch 2026 Volume 42 – Number 4

  2. The edit itself

    Not covered

    The exclusion is implemented as a claim edit on the drug code, not as a criteria review.

    NDC exclude from State Plan.

    New York State Department of HealthMarch 2026 Volume 42 – Number 4

  3. And the category, listed separately

    Not covered

    The same update repeats the exclusion as a general category, alongside sexual dysfunction and cosmetic drugs.

    Drugs used for the treatment of anorexia, weight loss or weight gain pursuant to SSA §1927(d)(2)

    New York State Department of HealthMarch 2026 Volume 42 – Number 4

  4. A separate restriction arrived through the review board

    Conditions apply

    New York's live GLP-1 activity is about combinations, not obesity: taking a DPP-4 inhibitor and a GLP-1 together now needs authorization.

    Prior authorization will be required for patients utilizing a Dipeptidyl Peptidase-4 (DPP-4) Inhibitor and Glucagon-like Peptide-1 (GLP-1) Receptor Agonist concurrently.

    New York State Department of Health, Medicaid Drug Utilization Review BoardFriday, October 3, 2025

  5. Voted unanimously

    Context

    The board recorded sixteen in favor and none against, and the commissioner adopted it as recommended.

    Vote: In favor 16

    New York State Department of Health, Medicaid Drug Utilization Review BoardFriday, October 3, 2025

  6. Which issue this is

    Context

    The rejection table is in a numbered monthly update, so it can be checked against later issues as the list changes.

    March 2026 Volume 42 – Number 4

    New York State Department of HealthMarch 2026 Volume 42 – Number 4

Which of these companies serve New York?

Of the 242 companies we grade, 25 publish a list of the states they are licensed in. We checked 214 more and found no such list on any page we read; 3 we have not checked either way.

18 of those lists name New York: Gala Health, Care Bare Rx, Vita Bella, TelePeptide, Levity, Wisp, WePeptideRx, TeleClinic, Tyde Wellness, Willow, The Virtual NP, VevaRx, Trimi, Enhance MD, HumeCare+, Rx.com, Mojoon and Peak Wellness. That is a licensure claim each company makes about itself, not something we checked with a state board.

A published list is a starting point, not a guarantee. If availability decides your choice, ask before you pay and get the answer in writing.

Sources

Each document below was fetched and read on the date shown beside it, which is the date printed on the document — not always the date in its web address. All of them were read in September 2026, the same session as the rest of this page.

Nothing on this page is medical advice, and nobody here is a clinician. Coverage rules change; check the linked document before you rely on it.